Literature DB >> 11715947

Non-viral amplification systems for gene transfer: vectors based on alphaviruses.

C Smerdou1, P Liljeström.   

Abstract

Non-viral self-replicating vectors based on defective viral genomes have been developed for a number of different alphaviruses including Semliki Forest virus (SFV), Sindbis virus (SIN) and Venezuelan equine encephalitis virus (VEE). These vectors can be used for gene delivery as naked RNA or DNA. Recombinant alphavirus RNA can be synthesized in vitro from plasmids containing the alphavirus replicon under the control of a prokaryotic promoter such as SP6 or T7. These self-replicating RNAs have been able to induce protective immune responses in vivo, probably due to the high level of expression of the recombinant antigen in the transfected cells. However, alphavirus vectors based on the direct delivery DNA are probably a better choice due to their higher stability and lower production cost. In these vectors, the alphavirus replicon is placed under the control of a RNA polymerase II promoter. These vectors are more efficient than conventional plasmids in inducing both humoral and cellular immune responses in small animals, allowing the use of significant smaller amounts of DNA for immunization. In addition, due to the transient nature of the alphavirus replicons, possible problems associated with DNA integration into host chromosomes are eliminated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11715947

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN: 1464-8431


  19 in total

1.  Mimicking live flavivirus immunization with a noninfectious RNA vaccine.

Authors:  Regina M Kofler; Judith H Aberle; Stephan W Aberle; Steven L Allison; Franz X Heinz; Christian W Mandl
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

2.  Nonviral delivery of self-amplifying RNA vaccines.

Authors:  Andrew J Geall; Ayush Verma; Gillis R Otten; Christine A Shaw; Armin Hekele; Kaustuv Banerjee; Yen Cu; Clayton W Beard; Luis A Brito; Thomas Krucker; Derek T O'Hagan; Manmohan Singh; Peter W Mason; Nicholas M Valiante; Philip R Dormitzer; Susan W Barnett; Rino Rappuoli; Jeffrey B Ulmer; Christian W Mandl
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-20       Impact factor: 11.205

3.  RNA-based vaccination: sending a strong message.

Authors:  David B Weiner
Journal:  Mol Ther       Date:  2013-03       Impact factor: 11.454

4.  A cationic nanoemulsion for the delivery of next-generation RNA vaccines.

Authors:  Luis A Brito; Michelle Chan; Christine A Shaw; Armin Hekele; Thomas Carsillo; Mary Schaefer; Jacob Archer; Anja Seubert; Gillis R Otten; Clayton W Beard; Antu K Dey; Anders Lilja; Nicholas M Valiante; Peter W Mason; Christian W Mandl; Susan W Barnett; Philip R Dormitzer; Jeffrey B Ulmer; Manmohan Singh; Derek T O'Hagan; Andrew J Geall
Journal:  Mol Ther       Date:  2014-07-16       Impact factor: 11.454

5.  Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion.

Authors:  Willy M Bogers; Herman Oostermeijer; Petra Mooij; Gerrit Koopman; Ernst J Verschoor; David Davis; Jeffrey B Ulmer; Luis A Brito; Yen Cu; Kaustuv Banerjee; Gillis R Otten; Brian Burke; Antu Dey; Jonathan L Heeney; Xiaoying Shen; Georgia D Tomaras; Celia Labranche; David C Montefiori; Hua-Xin Liao; Barton Haynes; Andrew J Geall; Susan W Barnett
Journal:  J Infect Dis       Date:  2014-09-18       Impact factor: 5.226

6.  Optimization of Lipid Nanoformulations for Effective mRNA Delivery.

Authors:  Dekui Zhang; TiYun Han; Huiling Chen; Xuan Ren; Shi Xu
Journal:  Int J Nanomedicine       Date:  2022-07-02

7.  Relation between viral fitness and immune escape within the hepatitis C virus protease.

Authors:  J Söderholm; G Ahlén; A Kaul; L Frelin; M Alheim; C Barnfield; P Liljeström; O Weiland; D R Milich; R Bartenschlager; M Sällberg
Journal:  Gut       Date:  2005-08-16       Impact factor: 23.059

8.  Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model.

Authors:  Clement A Meseda; Anne E Mayer; Arunima Kumar; Alonzo D Garcia; Joseph Campbell; Paul Listrani; Jody Manischewitz; Lisa R King; Hana Golding; Michael Merchlinsky; Jerry P Weir
Journal:  Clin Vaccine Immunol       Date:  2009-07-15

9.  RNA replicon delivery via lipid-complexed PRINT protein particles.

Authors:  Jing Xu; J Christopher Luft; Xianwen Yi; Shaomin Tian; Gary Owens; Jin Wang; Ashley Johnson; Peter Berglund; Jonathan Smith; Mary E Napier; Joseph M DeSimone
Journal:  Mol Pharm       Date:  2013-08-21       Impact factor: 4.939

10.  Role of TLR3 in the immunogenicity of replicon plasmid-based vaccines.

Authors:  S S Diebold; O Schulz; L Alexopoulou; W W Leitner; R A Flavell; C Reis e Sousa
Journal:  Gene Ther       Date:  2008-12-04       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.